An Insight on Oncotarget

A popular journal, Oncotarget is focused on the research of Oncology. The journal is published by the Impact Journals two times a week. Since its inception several years ago, Oncotarget has been able to transform the lives of numerous individuals. In 2015 only, Oncotarget is said to have published many papers more than any other journal in its category. The main aim of the journal is to make sure that they content get to be read by as many people as possible. They also seek to avail their content about scientific research to their readers as fast as possible. Oncotarget has been able to create many job opportunities for many people who serve on the journal’s editorial board and content contributors.Oncotarget mostly focuses its content on oncology although it has recently ventured into other sectors.

The journal has earned a reputation as a very reliable and efficient journal that is committed to revolutionizing the medical field. The primary objective behind the formation of Oncotarget was to bring together a multidisciplinary approach in the fields of endocrinology, metabolism, cancer, pharmacology and anti-aging. Oncotarget allows its readers to print any issue that they publish in case of a special demand. Readers can visit the journal’s site, read articles, review and even download them provided they cite the source of the content. The papers that are published by Oncotarget are judged mostly on their scientific merit as well as unbiased analysis.

Before being published, two or more editors at the journal have to review the content being published.The editors working at Oncotarget have a lot of experience and expertise in the scientific world. The Chief Editor at Oncotarget is Mikhail Blagosklonny. Mikhail is an experienced scientist who specializes in the field of oncology, cancer and anti-aging. Andrei Gudkov also serves as a chief editor at the oncology journal. The two editors have a lot of expertise and experience in the scientific world. The journal uses the latest technology in relaying scientific research results. The success of Oncotarget can be attributed to the hard work of its editor. The journal has managed to win several awards due to its contributions to the scientific world.


Eric Lefkofsky Startup Tempus to Help in Cancer Fight

Technology company Tempus, founded in 2015 by Eric Lefkofsky, wants to provide doctors at the University of Chicago data to assist in treatment of patients with breast cancer.Tempus has announced a partnership with the University of Chicago Medicine to provide molecular sequencing and analysis to breast cancer specialists to help them tailor individualized treatment plans for patients. Tempus will analyze data from about 1,000 breast cancer patients to assist in uncovering patterns to predict how patients will respond to treatment.Tempus uses machine learning and genomic sequencing to help with the treatment plans. The goal is for this information to lead to better treatment and patient outcomes.

Dr. Olufunmilayo Olopade, professor of medicine and human genetics and dean for global health at the University of Chicago, said in a statement that specific genetic data could help physicians make better informed and targeted treatment decisions.In recent months, Tempus has entered into partnerships with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, the Mayo Clinic, Rush University Medical Center, Penn Medicine and the University of Michigan to use information to battle cancer.In addition to acting as the CEO of Tempus, Eric Lefkofsky is also a founding partner of Lightbank and the co-founder and Chairman of Groupon, Mediaocean, Echo Global Logistics and InnerWorkings.

In 2006 Eric Lefkofsky established the Lefkofsky Family Foundation, a charitable foundation to advance high-impact initiatives that enhance lives in the communities served. Among other positions, Lefkofsky serves as a Trustee of Lurie Children’s Hospital of Chicago, The Art Institute of Chicago, The Museum of Science and Industry and World Business Chicago. He is an adjunct professor at the University of Chicago and author of Accelerated Disruption. He graduated from the University of Michigan in 1991 and received his Juris Doctor from the University of Michigan Law School in 1993.